$68.59
2.49% day before yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Incyte Stock price

$68.59
-0.26 0.38% 1M
-3.78 5.22% 6M
-0.48 0.69% YTD
+6.30 10.11% 1Y
-12.37 15.28% 3Y
-31.97 31.79% 5Y
-44.41 39.30% 10Y
+60.02 700.35% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-1.75 2.49%
ISIN
US45337C1027
Symbol
INCY
Sector
Industry

Key metrics

Basic
Market capitalization
$13.3b
Enterprise Value
$10.9b
Net debt
positive
Cash
$2.4b
Shares outstanding
193.8m
Valuation (TTM | estimate)
P/E
685.9 | 11.6
P/S
3.0 | 2.8
EV/Sales
2.5 | 2.3
EV/FCF
36.0
P/B
3.6
Financial Health
Equity Ratio
63.3%
Return on Equity
1.0%
ROCE
5.9%
ROIC
2.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.4b | $4.8b
EBITDA
$261.9m | $1.5b
EBIT
$238.0m | $1.4b
Net Income
$21.3m | $1.1b
Free Cash Flow
$302.7m
Growth (TTM | estimate)
Revenue
17.1% | 13.5%
EBITDA
-64.4% | 1,027.6%
EBIT
-66.6% | 1,177.3%
Net Income
-97.1% | 3,412.1%
Free Cash Flow
-61.7%
Margin (TTM | estimate)
Gross
93.2%
EBITDA
5.9% | 31.7%
EBIT
5.4%
Net
0.5% | 23.8%
Free Cash Flow
6.9%
More
EPS
$0.1
FCF per Share
$1.6
Short interest
6.0%
Employees
3k
Rev per Employee
$1.6m
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Incyte forecast:

17x Buy
52%
15x Hold
45%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a Incyte forecast:

Buy
52%
Hold
45%
Sell
3%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4,413 4,413
17% 17%
100%
- Direct Costs 300 300
27% 27%
7%
4,113 4,113
16% 16%
93%
- Selling and Administrative Expenses 1,247 1,247
9% 9%
28%
- Research and Development Expense 2,604 2,604
58% 58%
59%
262 262
64% 64%
6%
- Depreciation and Amortization 24 24
5% 5%
1%
EBIT (Operating Income) EBIT 238 238
67% 67%
5%
Net Profit 21 21
97% 97%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Business Wire
2 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic...
Positive
Seeking Alpha
10 days ago
Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Jakafi and Opzelura remain the company's primary revenue drivers, with Jakafi delivering $709M in Q1 2025 and strong growth across indications. Q1 2025 revenue grew 20% year-over-year to $1.05B, prompting management to raise full-year guidance, reflecting confidence in ...
Neutral
Business Wire
10 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today